For instance, CD95 loss limits tumour incidence in KRASG12D+/−/PTEN−/−-driven ovarian cancer and diethlynitrosamine (DEN)-induced hepatocellular carcinoma (HCC) models [114]. The gene discussed is FAS; the disease is neoplasm.